GB9921229D0 - Compositions - Google Patents

Compositions

Info

Publication number
GB9921229D0
GB9921229D0 GBGB9921229.2A GB9921229A GB9921229D0 GB 9921229 D0 GB9921229 D0 GB 9921229D0 GB 9921229 A GB9921229 A GB 9921229A GB 9921229 D0 GB9921229 D0 GB 9921229D0
Authority
GB
United Kingdom
Prior art keywords
compositions
sugars
reducing
obesity
uptake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9921229.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MED EQ AS
Original Assignee
MED EQ AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MED EQ AS filed Critical MED EQ AS
Priority to GBGB9921229.2A priority Critical patent/GB9921229D0/en
Publication of GB9921229D0 publication Critical patent/GB9921229D0/en
Priority to DE60002484T priority patent/DE60002484T2/de
Priority to PCT/GB2000/003472 priority patent/WO2001017369A1/en
Priority to AU70269/00A priority patent/AU777044B2/en
Priority to GB0127158A priority patent/GB2364498A/en
Priority to ES00958855T priority patent/ES2199174T3/es
Priority to JP2001521170A priority patent/JP2003508467A/ja
Priority to DK00958855T priority patent/DK1213972T3/da
Priority to EP00958855A priority patent/EP1213972B1/en
Priority to PT00958855T priority patent/PT1213972E/pt
Priority to AT00958855T priority patent/ATE238689T1/de
Priority to KR1020027003087A priority patent/KR100594520B1/ko
Priority to CA002383720A priority patent/CA2383720A1/en
Priority to NZ518167A priority patent/NZ518167A/xx
Priority to NO20021160A priority patent/NO314922B1/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
GBGB9921229.2A 1999-09-08 1999-09-08 Compositions Ceased GB9921229D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
NZ518167A NZ518167A (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss
JP2001521170A JP2003508467A (ja) 1999-09-08 2000-09-08 アルファ−アミラーゼインヒビターと、腸からの「速効性糖類（ｆａｓｔｓｕｇａｒｓ）」の吸収を減少させるために適する少なくとも一種類の生理学的に許容可能な化合物とを含む組成物
EP00958855A EP1213972B1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of "fast sugars"
AU70269/00A AU777044B2 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of "fast sugars"
GB0127158A GB2364498A (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption
ES00958855T ES2199174T3 (es) 1999-09-08 2000-09-08 Composicion que comprende un inhibidor de alfa-amilasa y al menos un compuesto fisiologicamente aceptable capaz de reducir la absorcion intestinal de "azucares rapidos".
DE60002484T DE60002484T2 (de) 1999-09-08 2000-09-08 Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält
DK00958855T DK1213972T3 (da) 1999-09-08 2000-09-08 Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen
PCT/GB2000/003472 WO2001017369A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'
PT00958855T PT1213972E (pt) 1999-09-08 2000-09-08 Composicao compreendendo um inibidor da alfa-amilase e pelo menos um composto fisiologicamente aceitavel capaz de reduzir a absorcao intestinal dos "acucares rapidos"
AT00958855T ATE238689T1 (de) 1999-09-08 2000-09-08 ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT
KR1020027003087A KR100594520B1 (ko) 1999-09-08 2000-09-08 알파-아밀라제 억제제와, “패스트 당”의 장내 흡수를저감시킬 수 있는 1종 이상의 생리학적으로 허용되는화합물을 포함하는 조성물
CA002383720A CA2383720A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of "fast sugars"
NO20021160A NO314922B1 (no) 1999-09-08 2002-03-08 Blanding omfattende en alfa-amylasehemmer, samt anvendelse derav

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions

Publications (1)

Publication Number Publication Date
GB9921229D0 true GB9921229D0 (en) 1999-11-10

Family

ID=10860574

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9921229.2A Ceased GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
GB0127158A Withdrawn GB2364498A (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0127158A Withdrawn GB2364498A (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption

Country Status (14)

Country Link
EP (1) EP1213972B1 (https=)
JP (1) JP2003508467A (https=)
KR (1) KR100594520B1 (https=)
AT (1) ATE238689T1 (https=)
AU (1) AU777044B2 (https=)
CA (1) CA2383720A1 (https=)
DE (1) DE60002484T2 (https=)
DK (1) DK1213972T3 (https=)
ES (1) ES2199174T3 (https=)
GB (2) GB9921229D0 (https=)
NO (1) NO314922B1 (https=)
NZ (1) NZ518167A (https=)
PT (1) PT1213972E (https=)
WO (1) WO2001017369A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US6797287B2 (en) 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US7108869B2 (en) 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
ITMI20030391A1 (it) * 2003-03-04 2004-09-05 S I I T S R L Servizio Internaz Ionale Imballa Formulazioni anticarie a base di faseolamina.
ITMI20052450A1 (it) * 2005-12-22 2007-06-23 Indena Spa Estratti di phaseolus vulgaris loro uso e formulazioni che li contengono
JP5285852B2 (ja) * 2006-12-28 2013-09-11 株式会社ファンケル Ｄｆａｉｉｉの製造方法及びｄｆａｉｉｉ高含有植物エキス
US20100330137A1 (en) * 2008-03-10 2010-12-30 Mauro Mantovani High bioavailability formulation of mangosteen and manufacturing process thereof
CA2751227C (en) * 2009-02-02 2021-10-26 Laila Nutraceuticals Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
CN103478738B (zh) * 2013-09-17 2016-02-10 深圳太太药业有限公司 一种具有减肥塑身及体重管理作用的组合物
CN106686988A (zh) * 2014-09-19 2017-05-17 雀巢产品技术援助有限公司 用于降低伴侣动物碳水化合物吸收的方法和配制物
CN106036342A (zh) * 2016-06-14 2016-10-26 安徽平唐微食疗科技有限公司 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法
IT201700078389A1 (it) * 2017-07-13 2019-01-13 Mv Medical Solutions Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi.
AU2020281621B2 (en) * 2019-05-24 2025-09-11 Cosucra Groupe Warcoing S.A. Composition comprising inulin and protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010258A (en) * 1974-03-15 1977-03-01 Ajinomoto Co., Inc. Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
JP2757405B2 (ja) * 1988-12-09 1998-05-25 日清製粉株式会社 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
WO2000043036A2 (en) * 1999-01-22 2000-07-27 Hunza Di Maria Carmela Marazzita S.A.S. Lipoprotein complexes and compositions containing them

Also Published As

Publication number Publication date
CA2383720A1 (en) 2001-03-15
DK1213972T3 (da) 2003-08-18
EP1213972B1 (en) 2003-05-02
DE60002484D1 (de) 2003-06-05
PT1213972E (pt) 2003-09-30
ATE238689T1 (de) 2003-05-15
AU777044B2 (en) 2004-09-30
AU7026900A (en) 2001-04-10
EP1213972A1 (en) 2002-06-19
KR20020045605A (ko) 2002-06-19
ES2199174T3 (es) 2004-02-16
NO314922B1 (no) 2003-06-16
GB2364498A (en) 2002-01-30
KR100594520B1 (ko) 2006-07-19
NO20021160L (no) 2002-03-27
NO20021160D0 (no) 2002-03-08
NZ518167A (en) 2003-03-28
DE60002484T2 (de) 2004-03-18
GB0127158D0 (en) 2002-01-02
JP2003508467A (ja) 2003-03-04
WO2001017369A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
GB9921229D0 (en) Compositions
BG104680A (en) Celecoxib compositions
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
ZA983618B (en) Novel cyclosporin derivatives their preparation and the pharmaceutical compositions which contain them
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NZ508877A (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-L-carnitine and genistein
EP3453379A3 (en) Micropigment mixtures
AU2002358348A1 (en) Soft drink replacer
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
EP0930019A3 (en) Composition for treating obesity and foods and drinks containing the same
CA2356320A1 (en) Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
AP2001002377A0 (en) Substituted phenoxyacetic acids.
NZ517443A (en) Stabilization of parboiled rice bran by acid treatment
DK1194139T3 (da) Næringsmæssig sammensætning til vedligeholdelse af vægt
CA2284278A1 (en) Histone containing composition to treat rheumatoid arthritis
CA2501321A1 (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
WO2004060081A8 (en) A method of improving nutrient utilisation by a mammal and a composition for use therein
EP1068868A3 (en) Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
GB9819317D0 (en) Organic compounds
NZ505933A (en) Incorporation of cholesterol lowering agents into confectionery dosage forms
IL150977A (en) Use of protein source for preparation of a nutitional composition for maintaining or improving the synthesis of mucins
CA2314817A1 (en) Synergistic agents for enhancing tissue repair
AR013274A1 (es) Producto de cereal cocido enriquecido, organolepticamente aceptable para consumo humano.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)